Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 1
2013 1
2015 1
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ilaria lean
Your search for Ilarie Leșan retrieved no results
Measurement of body composition as a surrogate evaluation of energy balance in obese patients.
Rotella CM, Dicembrini I. Rotella CM, et al. World J Methodol. 2015 Mar 26;5(1):1-9. doi: 10.5662/wjm.v5.i1.1. eCollection 2015 Mar 26. World J Methodol. 2015. PMID: 25825693 Free PMC article. Review.
Energy restriction alone is an effective strategy to achieve an early and significant weight loss, however it results in a reduction of both fat and lean mass therefore promoting or aggravating an unfavourable body composition (as sarcobesity) in terms of mortality and com …
Energy restriction alone is an effective strategy to achieve an early and significant weight loss, however it results in a reduction of both …
Plasma 2-arachidonoylglycerol is a biomarker of age and menopause related insulin resistance and dyslipidemia in lean but not in obese men and women.
Fanelli F, Mezzullo M, Belluomo I, Di Lallo VD, Baccini M, Ibarra Gasparini D, Casadio E, Mastroroberto M, Vicennati V, Gambineri A, Morselli-Labate AM, Pasquali R, Pagotto U. Fanelli F, et al. Mol Metab. 2017 Mar 21;6(5):406-415. doi: 10.1016/j.molmet.2017.03.005. eCollection 2017 May. Mol Metab. 2017. PMID: 28462075 Free PMC article.
CONCLUSIONS: Plasma 2AG is a biomarker of clustering metabolic dysfunctions, especially in lean men and menopausal women, and could be of help in identifying subjects with elevated cardiometabolic risk despite a healthy anthropometric appearance....
CONCLUSIONS: Plasma 2AG is a biomarker of clustering metabolic dysfunctions, especially in lean men and menopausal women, and could b …
Profiling plasma N-Acylethanolamine levels and their ratios as a biomarker of obesity and dysmetabolism.
Fanelli F, Mezzullo M, Repaci A, Belluomo I, Ibarra Gasparini D, Di Dalmazi G, Mastroroberto M, Vicennati V, Gambineri A, Morselli-Labate AM, Pasquali R, Pagotto U. Fanelli F, et al. Mol Metab. 2018 Aug;14:82-94. doi: 10.1016/j.molmet.2018.06.002. Epub 2018 Jun 6. Mol Metab. 2018. PMID: 29935920 Free PMC article.
AEA and OEA abundances in premenopausal, and PEA and OEA abundances in lean menopausal women, were directly associated with hypertension. ...
AEA and OEA abundances in premenopausal, and PEA and OEA abundances in lean menopausal women, were directly associated with hypertens …
Integration of transcriptomic data in a genome-scale metabolic model to investigate the link between obesity and breast cancer.
Granata I, Troiano E, Sangiovanni M, Guarracino MR. Granata I, et al. BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):162. doi: 10.1186/s12859-019-2685-9. BMC Bioinformatics. 2019. PMID: 30999849 Free PMC article.
RESULTS: In this work, we exploited gene expression data of postmenopausal breast cancer obese and lean patients to simulate a curated GEM of the human adipocyte, available in the Human Metabolic Atlas database. ...
RESULTS: In this work, we exploited gene expression data of postmenopausal breast cancer obese and lean patients to simulate a curate …
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP, Zimmermann A, Brown MP, Ilaria RL Jr, Millward MJ. Kirkwood JM, et al. Cancer. 2011 Oct 15;117(20):4732-9. doi: 10.1002/cncr.26068. Epub 2011 Mar 31. Cancer. 2011. PMID: 21456002 Free article. Clinical Trial.
METHODS: Tasisulam was administered intravenously on Day 1 of 21-day cycles according to a lean body weight-based dosing algorithm targeting a peak plasma concentration (C(max)) of 420 mug/mL. ...
METHODS: Tasisulam was administered intravenously on Day 1 of 21-day cycles according to a lean body weight-based dosing algorithm ta …
A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors.
Simon GR, Ilaria RL Jr, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. Simon GR, et al. Cancer Chemother Pharmacol. 2011 Nov;68(5):1233-41. doi: 10.1007/s00280-011-1593-0. Epub 2011 Mar 23. Cancer Chemother Pharmacol. 2011. PMID: 21431416 Free PMC article. Clinical Trial.
Pharmacokinetic analysis indicated that C(max) negatively correlates with lean body weight (LBW). Thus, the dosing regimen was revised using a LBW-based algorithm targeting a specific C(max). ...
Pharmacokinetic analysis indicated that C(max) negatively correlates with lean body weight (LBW). Thus, the dosing regimen was revise …
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
Ryan CW, Matias C, Agulnik M, Lopez-Pousa A, Williams C, de Alwis DP, Kaiser C, Miller MA, Ermisch S, Ilaria R Jr, Keohan ML. Ryan CW, et al. Invest New Drugs. 2013 Feb;31(1):145-51. doi: 10.1007/s10637-012-9819-5. Epub 2012 Apr 27. Invest New Drugs. 2013. PMID: 22539091 Clinical Trial.
METHODS: Tasisulam was administered intravenously on day 1 of 21-day cycles according to a lean body weight-based dosing algorithm targeting a peak plasma concentration (C(max)) of 420 mug/mL; a 360-mug/mL dose level was also explored. ...
METHODS: Tasisulam was administered intravenously on day 1 of 21-day cycles according to a lean body weight-based dosing algorithm ta …